1236965

Mark Savant, M.D. — FEI 3030218581

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
April 17, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
San Francisco, CA (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
753121 CFR 312.62(c)Record retention
756021 CFR 312.60FD-1572, protocol compliance
756221 CFR 312.60Informed consent